SGLT2抑制剂与GLP-1受体激动剂治疗1型糖尿病的肾脏血管结局:一项真实世界研究
基于TriNetX平台的回顾性队列研究纳入1822例接受GLP-1 RA和992例接受SGLT2i治疗的1型糖尿病患者,两者均降低HbA1c(SGLT2i -2.6 mmol/mol,GLP-1 RA -5.4 mmol/mol)。SGLT2i组5年eGFR保持优于GLP-1 RA组,但DKA和尿路感染风险更高,心力衰竭、CKD和全因住院风险更低。
要点
- SGLT2i与GLP-1 RA均能降低1型糖尿病患者HbA1c,SGLT2i降幅为-2.6 mmol/mol,GLP-1 RA为-5.4 mmol/mol。
- SGLT2i组5年eGFR变化为+3.5 ml/min/1.73 m2,GLP-1 RA组为-7.2 ml/min/1.73 m2。
- SGLT2i组DKA风险(RR 2.08)和尿路感染/肾盂肾炎风险(RR 2.27)高于GLP-1 RA组。
核心结论
- SGLT2i和GLP-1 RA作为1型糖尿病辅助治疗均有潜在获益。
- SGLT2i提供肾脏血管获益,但与GLP-1 RA相比DKA和尿路感染风险增加。
- 需要长期评估这些辅助治疗的疗效和安全性以指导其在1型糖尿病中的使用。
研究设计与样本
- 回顾性队列研究,使用TriNetX平台(全球协作网络,提供实时匿名医疗记录)。
- 纳入18岁及以上1型糖尿病患者,接受SGLT2i或GLP-1 RA治疗至少6个月。
- 分析治疗开始后5年的疗效、安全性和肾脏血管结局。
- 共识别196,691例1型糖尿病患者,13%在胰岛素基础上接受辅助降糖治疗。
- 核心分析纳入1822例接受GLP-1 RA治疗和992例接受SGLT2i治疗的患者。
主要发现
- SGLT2i组HbA1c降低-2.6 mmol/mol(-0.2%),GLP-1 RA组降低-5.4 mmol/mol(-0.5%)。
- SGLT2i组5年eGFR变化为+3.5 ml/min/1.73 m2,GLP-1 RA组为-7.2 ml/min/1.73 m2,包括已确诊慢性肾脏病的患者。
- SGLT2i组与GLP-1 RA组相比,DKA风险更高(RR 2.08 [95% CI 1.05, 4.12] p=0.0309),尿路感染/肾盂肾炎风险更高(RR 2.27 [95% CI 1.12, 4.55] p=0.019)。
- SGLT2i组与GLP-1 RA组相比,心力衰竭风险更低(RR 0.44 [95% CI 0.23, 0.83] p=0.0092),CKD风险更低(RR 0.49 [95% CI 0.28, 0.86] p=0.0118),全因住院风险更低(RR 0.59 [95% CI 0.46, 0.76] p≤0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要长期评估这些辅助治疗的疗效和安全性以指导其在1型糖尿病中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Insulin is the primary treatment for type 1 diabetes. However, alternative glucose-lowering therapies are used adjunctively, but importantly are off-label in type 1 diabetes. Little work has previously been undertaken to evaluate safety with long-term efficacy and cardio-renal benefits of such therapies. We sought to investigate the real-world impact of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with type 1 diabetes in relation to effect on blood glucose levels, adverse events and cardio-renal outcomes. METHODS: We performed a retrospective cohort study of all patients aged 18 or over with type 1 diabetes on the TriNetX platform, a global collaborative network providing access to real-time, anonymised medical records. We included patients who had been treated with an SGLT2i or GLP-1 RA for at least 6 months and analysed the efficacy, safety and cardio-renal outcomes 5 years after initiation of therapy. RESULTS: We identified 196,691 individuals with type 1 diabetes, 13% of whom were treated with adjunctive glucose-lowering therapy in addition to insulin. Included in the core analysis were 1822 patients treated with a GLP-1 RA and 992 individuals treated with an SGLT2i. Both agents provided clinically meaningful reductions in HbA1c (-2.6 mmol/mol [-0.2%] with SGLT2i and -5.4 mmol/mol [-0.5%] with GLP-1 RA). The SGLT2i treated cohort showed preservation of eGFR over a 5-year period compared with the GLP-1 RA treated cohort (+3.5 ml/min per 1.73 m2 vs -7.2 ml/min per 1.73 m2, respectively), including patients with established chronic kidney disease (CKD). The SGLT2i treated cohort experienced higher rates of diabetic ketoacidosis (DKA) (RR 2.08 [95% CI 1.05, 4.12] p=0.0309) and urinary tract infection/pyelonephritis (RR 2.27 [95% CI 1.12, 4.55] p=0.019) compared with the GLP-1 RA treated cohort. However, the SGLT2i treated cohort were less likely to develop heart failure (RR 0.44 [95% CI 0.23, 0.83] p=0.0092), CKD (RR 0.49 [95% CI 0.28, 0.86] p=0.0118) and be hospitalised for any cause (RR 0.59 [95% CI 0.46, 0.76] p≤0.0001) when compared with the GLP-1 RA treated cohort. CONCLUSIONS/INTERPRETATION: Both SGLT2is and GLP-1 RAs have potential benefits as adjunctive agents in type 1 diabetes. SGLT2is provide cardio-renal benefits, despite an increase in the risk of DKA and urinary tract infection compared with GLP-1 RA therapy. Long-term evaluation of the efficacy and safety of these adjunctive therapies is required to guide their use in individuals with type 1 diabetes.
引用
- Anson M, Zhao SS, Austin P, et al. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023. PMID: 37505282. doi:10.1007/s00125-023-05975-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。